Famicordtx Gene Therapies

FamicordTx (FCTx) is a leading innovative biotech, focused on making cell, and gene immunotherapy solutions more affordable and more accessible. A spin-off of the Polish Stem Cell Bank (PBKM), the largest stem cell bank in Europe, and the 3rd largest globally. A division of the Famicord Group. Immunotherapies are a treatment approach revolutionizing Oncology, which uses the immune system to fight cancer. Immunotherapies are one of the most promising advances in medicine, in particular cancer treatments, whereby the power of the bodies own immune system, which plays a critical role in infections, is turned against the cancer cells, giving a tool to T-cells to attack the cancer cells. One of these emerging therapies which is showing promise not only in blood related cancers, but is being explored with solid tumors is CAR-T therapy. The area of cell, gene and immunotherapies are an important step towards advancing personalized, precision medicine. The foundations of cancer treatment for decades has been surgery, chemotherapy, radiation therapy and pharmacology (drug treatments). Immuno-oncology therapies are now emerging in modern medicine as the “5th pillar” of cancer treatments. One form of immune-oncology therapy combines cell and gene therapy, making use of genetically modified T-cells to fight the infection. T-cells are a type of white blood cell that destroy foreign particles in the body, playing an important role in the immune system. CAR-T therapy uses a patient’s own T-cells, which are genetically modified in a laboratory to make a protein called a chimeric antigen receptor (CAR). When the modified T-cells are returned to the patient, the CAR enables the T-cells to seek out and destroy the cancer cells wherever they are found in the body. FCTx has joined the illustrious group of biotech companies globally revolutionizing cancer treatment.